Financial Results Summary

Income Statement Highlights (₹ in Lakhs)

Quarter Ended 30/09/2026 (Q2 FY2026):

  • Revenue from Operations (Net): ₹4,473.12
  • Total Income: ₹4,473.12 (Other Income: ₹0.00)
  • Total Expenses: ₹4,286.50
  • Purchase of Stock-in-Trade: ₹4,594.11
  • Changes in Inventories: -₹376.84 (decrease)
  • Employee Benefits Expense: ₹18.77
  • Finance Cost: ₹12.98
  • Depreciation and Amortization: ₹12.85
  • Other Expenses: ₹24.63
  • Profit Before Tax: ₹186.62
  • Tax Expenses: ₹30.30
  • Current Tax: ₹39.30
  • Deferred Tax: -₹9.00
  • Net Profit for the Period: ₹156.32
  • Basic EPS: ₹0.57
  • Diluted EPS: ₹0.57

Half Year Ended 30/09/2026 (H1 FY2026):

  • Revenue from Operations (Net): ₹8,164.51
  • Total Income: ₹8,164.62
  • Net Profit for the Period: ₹274.21
  • Basic EPS: ₹0.96
  • Diluted EPS: ₹0.96

Comparative Performance:

  • Q2 FY2026 Revenue increased 23% YoY from ₹3,635.89 lakh in Q2 FY2025
  • Q2 FY2026 Net Profit increased 193% YoY from ₹53.31 lakh in Q2 FY2025
  • H1 FY2026 Revenue increased 39% YoY from ₹5,871.01 lakh in H1 FY2025
  • H1 FY2026 Net Profit increased 328% YoY from ₹64.03 lakh in H1 FY2025

Capital Structure

  • Paid-up equity share capital (Face Value: ₹10 per share): ₹2,847.00 lakh as of 30/09/2026
  • Previous periods: ₹2,389.50 lakh (30/06/2026), ₹1,448.00 lakh (30/09/2025), ₹1,993.50 lakh (31/03/2026)

Assets and Liabilities Position (as at 30/09/2026)

  • Total Assets: ₹14,331.74 lakh
  • Total Equity: ₹6,534.79 lakh
  • Total Liabilities: ₹7,796.94 lakh
  • Current Assets: ₹13,561.89 lakh
  • Current Liabilities: ₹7,144.33 lakh
  • Cash and Cash Equivalents: ₹321.45 lakh

Cash Flow Statement (H1 FY2026)

  • Net Cash Used in Operating Activities: -₹1,366.50 lakh
  • Net Cash Used in Investing Activities: -₹296.93 lakh
  • Net Cash from Financing Activities: ₹1,689.02 lakh
  • Net Increase in Cash: ₹25.59 lakh

Governance and Approval

  • Board meeting held on 11th November, 2026 from 05:00 PM to 05:43 PM IST
  • Results approved by Board of Directors based on Audit Committee recommendation
  • Limited review conducted by CVS Balachandra Rao & Co., Chartered Accountants
  • The company has no subsidiaries, associates, or joint ventures

Business Segment

  • Single business segment: 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)'

Additional Information

  • Company changed name from TRIMURTHI LIMITED to reflect new business activity
  • Financial results prepared in accordance with Indian Accounting Standards (IND AS)
  • Results available on company website: https://novelixpharma.com/